Answers are grounded in this paper and cite their sources.
Background Two distinct subphenotypes (hyperinflammatory and hypoinflammatory) of ARDS have been identified. Neuromuscular blocking agents (NMBAs) are thought to provide benefit in ARDS by reducing inflammation. It is unclear whether ARDS subphenotypes respond differently to NMBAs. Research Question What is the heterogeneity of treatment effect (HTE) of NMBAs on 90-day mortality according to subphenotypes as determined by clinical variables in adult patients with ARDS using the data from the Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) clinical trial? Study Design and Methods In this retrospective study of the de-identified data set from the ROSE trial, subphenotypes were determined by clusters derived from clinical variables. The HTE of NMBAs was assessed following a Bayesian hierarchical logistic model for the primary outcome. Results Of the 715 patients analyzed from the ROSE trial, 73% of patients were identified as having subphenotype B (hyperinflammatory) and 27% were identified as having subphenotype A (hypoinflammatory). Patients with subphenotype B showed higher 90-day mortality compared with patients with subphenotype A (248 patients [47.7%] vs 64 patients [32.8%]; P < .001). Patients with subphenotype A receiving cisatracurium showed a lower 90-day mortality than those receiving usual care (31 patients [29.2%] vs 33 patients [37.1%]). In contrast, patients classified with subphenotype B showed a similar 90-day mortality independent of the treatment allocation arm (120 patients [48.2%] vs 128 patients [47.2%] for cisatracurium and usual care, respectively). The probability of lower 90-day mortality (benefit) with the use of cisatracurium compared with usual care was higher in patients with subphenotype A than in patients with subphenotype B (85.6% vs 44.2%; OR, 0.74 [95% credible interval, 0.42-1.30] vs OR, 1.03 [95% credible interval, 0.73-1.44], respectively). Interpretation At the time of enrollment into the ROSE trial, most patients had ARDS subphenotype B (hyperinflammatory), and based on the subsequent Bayesian analysis, NMBA use would not result in a mortality benefit in these patients.
No takes yet. Share an insight, caveat, or question.
Duggal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: